Biotech Values

[ghmm]

Yeah I just though Shire would want US rights since by the time Genzyme's exclusivity runs out they'ld be pretty far behind (I doubt a lot of patients switch) so a new mechanism would be better.

I am curious how Shire would place these with their ERT as my understanding is they are not meant to be used in a complimentary fashion.

Wonder if someone at Shire is really after Genzyme. What will this is be like 4-5 therapies competing directly against them?

I think genisi pointed out that enrollment for the Gaucher drug was slow.